OPKO Health (OPK) shares tumbled 6.25% in pre-market trading on Friday, following the release of its Q2 2025 financial results and a disappointing outlook for the third quarter. The biopharmaceutical and diagnostics company is facing headwinds as analysts project a loss and declining revenue for the upcoming quarter.
According to the latest earnings preview, OPKO Health is expected to report a loss of 7 cents per share for the quarter ending September 30, 2025. Analysts estimate a 3.7% decrease in revenue to $167.222 million, down from $173.6 million in the same period last year. This projection reflects ongoing challenges in the company's business segments and may have spooked investors.
Adding to the pessimistic sentiment, the mean earnings estimate for OPKO Health has fallen by about 4.4% over the past three months, indicating a deteriorating outlook among analysts. Despite these challenges, it's worth noting that the current average analyst rating on OPKO shares remains a "strong buy," with a median 12-month price target of $3.00, significantly above its last closing price. However, the market seems to be focusing on the near-term headwinds, as evidenced by today's pre-market decline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.